Jorge Bartual Bardisa, Carolina Vizcaíno Díaz, María Jesús Ferrández Berenguer
{"title":"早期表面活性剂能改善晚期早产儿的预后吗?新生儿重症监护病房回顾性研究。","authors":"Jorge Bartual Bardisa, Carolina Vizcaíno Díaz, María Jesús Ferrández Berenguer","doi":"10.1016/j.medine.2025.502161","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To compare the early administration of surfactant, before 12 h of life, versus late, in late preterm neonates (born between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation), with moderate-severe respiratory distress.</p><p><strong>Design: </strong>Retrospective, observational, analytical, case-control study, with late preterm infants admitted between 2012-2021. It is divided into 2 groups: surfactant administered ≤ 12 h of life and >12 h and evolution is compared using univariate analysis.</p><p><strong>Setting: </strong>Neonatal Intensive Care Unit (NICU) level III of a Universitary Hospital.</p><p><strong>Patients or participants: </strong>57 patients, 30 in the early group and 27 in the late group.</p><p><strong>Inclusion criteria: </strong>neonates from 34<sup>+0</sup> to 36<sup>+6</sup> weeks of gestation, with respiratory distress syndrome, in need of non-invasive ventilation and surfactant.</p><p><strong>Interventions: </strong>None.</p><p><strong>Main variables of interest: </strong>Sociodemographic, clinical and evolutionary: redosing, duration of respiratory support, oxygen and time to stop requiring it after surfactant. Also, complications and length of hospitalization.</p><p><strong>Results: </strong>In the early group there was less need for redosing (3.3% vs 48.1%, P < .001) and a decrease in duration, in days, of stay in the NICU (7 vs 10.5, P .002), invasive mechanical ventilation (2.4 vs 3.9, P .034), total respiratory support (4.6 vs 6.6, P .005) and oxygen therapy (0.4 vs 2.8, P < .001). Also, lower incidence of pneumothorax (0% vs 33.3%, P .001). Furthermore, 12 h after administration, 83.4% maintained FiO2 0.21, compared to 44.4% in the late administration.</p><p><strong>Conclusions: </strong>In our study, early administration in late preterm infants provides benefits in terms of respiratory assistance and complications. We suggest expanding studies to establish recommendations in this group of patients.</p>","PeriodicalId":94139,"journal":{"name":"Medicina intensiva","volume":" ","pages":"502161"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Does early surfactant improve outcome in late preterm newborn? Retrospective study in a neonatal intensive care unit.\",\"authors\":\"Jorge Bartual Bardisa, Carolina Vizcaíno Díaz, María Jesús Ferrández Berenguer\",\"doi\":\"10.1016/j.medine.2025.502161\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To compare the early administration of surfactant, before 12 h of life, versus late, in late preterm neonates (born between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation), with moderate-severe respiratory distress.</p><p><strong>Design: </strong>Retrospective, observational, analytical, case-control study, with late preterm infants admitted between 2012-2021. It is divided into 2 groups: surfactant administered ≤ 12 h of life and >12 h and evolution is compared using univariate analysis.</p><p><strong>Setting: </strong>Neonatal Intensive Care Unit (NICU) level III of a Universitary Hospital.</p><p><strong>Patients or participants: </strong>57 patients, 30 in the early group and 27 in the late group.</p><p><strong>Inclusion criteria: </strong>neonates from 34<sup>+0</sup> to 36<sup>+6</sup> weeks of gestation, with respiratory distress syndrome, in need of non-invasive ventilation and surfactant.</p><p><strong>Interventions: </strong>None.</p><p><strong>Main variables of interest: </strong>Sociodemographic, clinical and evolutionary: redosing, duration of respiratory support, oxygen and time to stop requiring it after surfactant. Also, complications and length of hospitalization.</p><p><strong>Results: </strong>In the early group there was less need for redosing (3.3% vs 48.1%, P < .001) and a decrease in duration, in days, of stay in the NICU (7 vs 10.5, P .002), invasive mechanical ventilation (2.4 vs 3.9, P .034), total respiratory support (4.6 vs 6.6, P .005) and oxygen therapy (0.4 vs 2.8, P < .001). Also, lower incidence of pneumothorax (0% vs 33.3%, P .001). Furthermore, 12 h after administration, 83.4% maintained FiO2 0.21, compared to 44.4% in the late administration.</p><p><strong>Conclusions: </strong>In our study, early administration in late preterm infants provides benefits in terms of respiratory assistance and complications. We suggest expanding studies to establish recommendations in this group of patients.</p>\",\"PeriodicalId\":94139,\"journal\":{\"name\":\"Medicina intensiva\",\"volume\":\" \",\"pages\":\"502161\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicina intensiva\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.medine.2025.502161\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina intensiva","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medine.2025.502161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:比较中重度呼吸窘迫的晚期早产儿(妊娠34+0 ~ 36+6周)在出生后12 h之前早期给药与晚期给药的差异。设计:回顾性、观察性、分析性、病例对照研究,研究对象为2012-2021年间入院的晚期早产儿。将其分为两组:表面活性剂给药 ≤ 12 h的寿命和>12 h的寿命,并采用单变量分析比较进化。环境:大学医院新生儿重症监护病房(NICU)三级。患者或参与者:57例患者,早期组30例,晚期组27例。纳入标准:妊娠34+0 ~ 36+6周,伴有呼吸窘迫综合征,需要无创通气和表面活性剂的新生儿。干预措施:没有。感兴趣的主要变量:社会人口统计学、临床和进化:再给药、呼吸支持持续时间、氧气和表面活性剂后停止需要它的时间。还有并发症和住院时间。结果:在早期组中,重新给药的需求较少(3.3% vs 48.1%, P )。结论:在我们的研究中,晚期早产儿早期给药在呼吸辅助和并发症方面有好处。我们建议扩大研究,在这组患者中建立推荐。
Does early surfactant improve outcome in late preterm newborn? Retrospective study in a neonatal intensive care unit.
Objective: To compare the early administration of surfactant, before 12 h of life, versus late, in late preterm neonates (born between 34+0 and 36+6 weeks of gestation), with moderate-severe respiratory distress.
Design: Retrospective, observational, analytical, case-control study, with late preterm infants admitted between 2012-2021. It is divided into 2 groups: surfactant administered ≤ 12 h of life and >12 h and evolution is compared using univariate analysis.
Setting: Neonatal Intensive Care Unit (NICU) level III of a Universitary Hospital.
Patients or participants: 57 patients, 30 in the early group and 27 in the late group.
Inclusion criteria: neonates from 34+0 to 36+6 weeks of gestation, with respiratory distress syndrome, in need of non-invasive ventilation and surfactant.
Interventions: None.
Main variables of interest: Sociodemographic, clinical and evolutionary: redosing, duration of respiratory support, oxygen and time to stop requiring it after surfactant. Also, complications and length of hospitalization.
Results: In the early group there was less need for redosing (3.3% vs 48.1%, P < .001) and a decrease in duration, in days, of stay in the NICU (7 vs 10.5, P .002), invasive mechanical ventilation (2.4 vs 3.9, P .034), total respiratory support (4.6 vs 6.6, P .005) and oxygen therapy (0.4 vs 2.8, P < .001). Also, lower incidence of pneumothorax (0% vs 33.3%, P .001). Furthermore, 12 h after administration, 83.4% maintained FiO2 0.21, compared to 44.4% in the late administration.
Conclusions: In our study, early administration in late preterm infants provides benefits in terms of respiratory assistance and complications. We suggest expanding studies to establish recommendations in this group of patients.